<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01947777</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-145-11</org_study_id>
    <nct_id>NCT01947777</nct_id>
  </id_info>
  <brief_title>Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145</brief_title>
  <acronym>DDI</acronym>
  <official_title>A Phase 1, Open-Label, Single-Sequence, 2-Period Study to Evaluate the Effect of Rifampin (a CYP3A Inducer) on the Pharmacokinetics of IPI-145 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SecuraBio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SecuraBio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of rifampin, a cytochrome P450 3A (CYP3A) inducer, on the&#xD;
      pharmacokinetics (PK) of IPI-145; to assess the safety and tolerability of IPI-145 when&#xD;
      administered with rifampin in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In Treatment Period 1, subjects will receive a single 25 mg oral dose of IPI-145&#xD;
&#xD;
        -  In Treatment Period 2, on Days 3-9, the same subjects will receive once daily (QD) oral&#xD;
           doses of 600 mg rifampin; on Day 9, subjects will receive a single oral dose of 25 mg&#xD;
           IPI-145 concomitantly administered with 600 mg of rifampin&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (AUC) of IPI-145 and its metabolite, IPI-656</measure>
    <time_frame>Over 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (Cmax) of IPI-145 and its metabolite, IPI-656</measure>
    <time_frame>Over 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters (t1/2) of IPI-145 and its metabolite, IPI-656</measure>
    <time_frame>Over 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of IPI-145 and its metabolite, IPI-656</measure>
    <time_frame>Over 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events following administration of IPI-145, rifampin, and the combination.</measure>
    <time_frame>2 weeks</time_frame>
    <description>Safety Findings</description>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145</intervention_name>
    <description>25 mg oral capsule</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>2x 300 mg oral capsule</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men or women of non-childbearing potential between 18-50 years of age&#xD;
&#xD;
          -  Body Mass Index (BMI): 18.0 - 32.0 kg/m2&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from clinical&#xD;
             evaluations&#xD;
&#xD;
          -  Provided written informed consent prior to any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Evidence of clinically significant medical conditions&#xD;
&#xD;
          -  History of gastrointestinal disease or surgery that may affect drug absorption&#xD;
&#xD;
          -  Positive or indeterminate Tuberculosis -spot test at screening&#xD;
&#xD;
          -  Any active infection at the time of screening or admission&#xD;
&#xD;
          -  Consumption of any nutrients known to modulate cytochrome P450 enzyme activity within&#xD;
             14 days prior to administration of study drug, during the study, and until after&#xD;
             discharge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA International, Inc</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 18, 2013</study_first_submitted>
  <study_first_submitted_qc>September 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2013</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>DDI</keyword>
  <keyword>CYP3A</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

